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Abstract
Background: An in vitro electrophysiological assay system, which can assess compound effects and thus show
cardiotoxicity including arrhythmia risks of test drugs, is an essential method in the field of drug development and
toxicology.
Methods: In this study, high-throughput electrophysiological recordings of human embryonic kidney (HEK 293)
cells and Chinese hamster ovary (CHO) cells stably expressing human ether-a-go-go related gene (hERG) were
performed utilizing an automated 384-well-patch-clamp system, which records up to 384 cells simultaneously. hERG
channel inhibition, which is closely related to a drug-induced QT prolongation and is increasing the risk of sudden
cardiac death, was investigated in the high-throughput screening patch-clamp system.
Results: In the automated patch-clamp measurements performed here, Kv currents were investigated with high
efficiency. Various hERG channel blockers showed concentration-dependent inhibition, the 50 % inhibitory
concentrations (IC50) of those blockers were in good agreement with previous reports.
Conclusions: The high-throughput patch-clamp system has a high potential in the field of pharmacology,
toxicology, and cardiac physiology, and will contribute to the acceleration of pharmaceutical drug development
and drug safety testing.
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Background
At present although the cost of pharmaceutical drug de-
velopment has been progressing, new pharmaceutical
drugs finally approved and launched into the market is
decreasing steadily. In 2001, while 30 % of pharmaceut-
ical drugs, which were tested clinically, were abandoned
because of the lack of efficacy, 30 % of others were also
abandoned because of safety concerns such as cardio-
toxicities including ion channel inhibition [1, 2]. Ion
channels are major targets of pharmaceutical drugs, it is
shown that more than 13 % of clinically used drugs
act primarily on ion channel proteins, these drugs are
estimated to be worth more than $12 billion world-
wide [3]. Therefore, the development of an in vitro
electrophysiological assay system, which can detect
the efficacy of candidate drugs or cardiotoxicity in-
cluding arrhythmia risks is strongly demanded in the
field of pharmacological development and drug safety
testing. An assay system using cells expressing human
ion channels has a powerful potential when it comes to re-
ducing the amount of animal experiments. In addition,
utilizing cells expressing human ion channels is expected
to be an accurate assessment, because there might be dif-
ferent reactivity against drugs between human and animal
ion channels. For example, the heartbeat of a mouse is
around 600 beats per minute, which is tenfold faster than
that of human beings, thus, the duration of the action po-
tential is much shorter and ion channels have different
properties [4]. Furthermore, the usage of mammalian cells
expressing human ion channel genes is more suitable than
Xenopus oocytes expressing the genes, which may be less
sensitive to drug inhibition [5–7].
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A patch-clamp system allows for investigation of the
electrophysiological function of ion channels, and was
first described by Neher and Sakmann who were
awarded the Nobel Prize in Medicine in 1991 [8, 9].
While the technology is an essential method in the field
of pharmacology, toxicology, and cardiac physiology, a
conventional patch-clamp setup is generally thought
to be demanding and needs high levels of manual
dexterity, knowledge and dedication of the experi-
menter. An automated patch-clamp system on the
other hand is easy to use compared to conventional
patch-clamping [10–12].
In this study a high-throughput electrophysiological
screening of human embryonic kidney (HEK 293) cells
and Chinese hamster ovary (CHO) cells stably express-
ing human ether-a-go-go related gene (hERG) was per-
formed utilizing an automated 384-well-patch-clamp
system. hERG channel inhibition of various blockers was
analyzed, and the 50 % inhibitory concentrations (IC50)
were compared to literature values.
Methods
Cell culture and cell preparation for patch-clamp analysis
In this study, HEK 293-hERG cells (Merck Millipore,
Billerica, MA, USA), which are HEK 293 cells stably ex-
pressing hERG, and CHO-hERG cells (Merck Millipore),
which are CHO cells stably expressing hERG, were used.
The HEK 293 cells were cultured in an equal volume
mixture of Dulbecco’s modified Eagle’s medium
(DMEM) and Nutrient Mixture F-12 (Invitrogen Life
Technologies, CA, USA) supplemented with 10 %
fetal bovine serum (FBS) (Invitrogen Life Technologies)
and 1 % penicillin/streptomycin (Invitrogen Life
Technologies), and the CHO cells were cultured in
Ham’s F12 medium (Invitrogen Life Technologies)
supplemented with 10 % FBS and 1 % penicillin/
streptomycin in a humidified 5 % CO2 atmosphere at
37 °C. For patch-clamp experiments, cultured cells on a
polystyrene culture dish (Sumitomo Bakelite, Tokyo,
Japan) were detached by Accutase (Innovative Cell
Technologies, Inc., CA, USA) at room temperature
for several minutes. A viable single cell suspension
was obtained by resuspension in patch clamp solution
with mild pipetting to avoid cell damage.
Patch-clamp analysis
Patch-clamp measurements were performed by an au-
tomated multi-well planar patch-clamp system the
SyncroPatch 384 Patch Engine (PE) (Nanion Technologies,
Munich, Germany) (Fig. 1a). The SyncroPatch 384 PE
was a patch-clamp module that was integrated into a
liquid handling robot owning a 384 pipetting head,
Biomek FX (Beckman Coulter, Brea, CA, USA). The sys-
tem was controlled by a dedicated software, PatchControl
384 (Nanion Technologies). In this device, 384 cells were
measured simultaneously. Patch-clamp recordings were
performed at room temperature using an intracellular so-
lution [50 mM KCl, 10 mM NaCl, 60 mM KF, 20 mM
EGTA, 10 mM HEPES (pH: 7.2) with 25 μM Escin for
(A) Over-view Patch clamp module 
(384-well)
(B) HEK293-hERG cells
(C) CHO-hERGcells
Fig. 1 Automated 384-well-patch-clamp system. a Left and right
photographs show the over-view and the patch-clamp module having
384-wells of the system, respectively. Those two photographs in (a) are
under the copyright of Nanion Technologies GmbH, and have been
used with permission from the company. The system could measure
membrane currents up to 384 cells simultaneously (b and c). The
numbers in (b) and (c) are the values of their seal resistances. For
example, the value, “567 M”, of 1A column in (b) is “567 MΩ”, and
that, “3.43 G”, of 1B column in (c) is “3.43 GΩ”. Green or gray panels
show complete experiments or incomplete experiments, respectively
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perforated patch (HEK 293-hERG cells) or without Escin
for whole cell recording (CHO-hERG cells)], and a stand-
ard bath solution [140 mM NaCl, 4 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 5 mM D-glucose, 10 mM HEPES
(pH: 7.4)]. Suspended single cells and drugs were freshly
prepared and applied into teflon reservoirs (Nanion
Technologies). In the automated patch-clamp system, the
following procedures were performed automatically. The
suspended single cells were aspirated from the reservoir,
pipetted into a planar 384-well patch-clamp chip, and
entrapped in the holes of the wells by an automatic-
ally applied vacuum. Seal generation, the establish-
ment of the perforated or standard whole cell mode
and also the electrophysiological recordings were con-
trolled by PatchControl 384. The application of drugs
into each well and the washout were also performed
automatically by the liquid handling robot. Concentration
response curves and IC50 values were calculated automat-
ically by another dedicated software, DataControl 384
(Nanion Technologies). Kv currents were elicited using a
voltage step from a holding potential (-80 mV) to +20 mV
for 1 s followed by a 1 s step to -50 mV.
hERG channel blockers
In this study, five hERG channel blockers [astemizole
(Sigma-Aldrich, St. Louis, MO, USA), cisapride monohy-
drate (Sigma-Aldrich), E-4031 hydrochloride (Wako
pure chemical, Tokyo, Japan), quinidine (Sigma-Aldrich),
and terfenadine (Sigma-Aldrich)] were used. Three con-
centrations of each drug were applied to the same cell
cumulatively and sequentially. Three hundred eighty-
four wells could be served with solution at the same
time due to the availability of the 384 pipetting head of
the system.
Results
Measurement of Kv currents in an automated
384-well-patch-clamp system
A patch-clamp investigation of HEK 293 cells or CHO
cells expressing hERG was performed in an automated
way by using a 384-well-patch-clamp system. For the
analysis, 10 μL of suspended cells (cell density: approxi-
mately 1 × 106 cells/mL) were applied to each well. A
complete experiment took approximately 15–25 min. Kv
currents were efficiently detected in the voltage-clamp
mode of the high-throughput system (Fig. 1b, c).
High-throughput assay on hERG inhibitors
The high-throughput system was used to investigate a
number of hERG channel inhibitors. The assay was per-
formed using five hERG channel blockers, which were
two antiarrhythmic drugs [E-4031 (Class III) and quini-
dine (Class Ia)] and three noncardiovascular drugs
[astemizole (antihistamine), cisapride (gastrokinetic), and
terfenadine (antihistamine)]. hERG currents were inhib-
ited by those drugs in a concentration dependent way
(Fig. 2a-e). The IC50 of those drugs were summarized in
Table 1. Those values were in good agreement with
previous reports (Table 1), showing the feasibility of
the automated high-throughput patch-clamp system
when performing a hERG screening.
Discussion
This study showed data of an automated patch-clamp
system, which records ion channel currents of up to 384
cells simultaneously. The system could detect hERG
channel inhibition in a high-throughput format using
HEK 293 cells overexpressing hERG channels. The
hERG channel is characterized as a voltage-gated in-
wardly rectifying potassium channel [13, 14], and plays a
key role in cardiac pathology because the gene links to
long QT syndrome, which is a hereditary disease causes
lethal ventricular arrhythmias [15–17]. Importantly, the
channel inhibition causes a drug-induced QT prolonga-
tion and is increasing the risk of sudden cardiac death
[5, 15–21]. Of drugs recently removed from the market
in the United States, one of the most common causes
has been QT prolongation-related cardiotoxicity [22].
Therefore, an optimal evaluation system of hERG chan-
nel blockers is important for detecting the cardiotoxicity
of candidate drugs. hERG channel screening of candi-
date drugs at an early stage in the drug development
process is accelerating the whole drug discovery proced-
ure. This study is proposing a high-throughput screen-
ing system for investigating hERG channel inhibition
using an automated multi-well-patch-clamp technol-
ogy. The patch-clamp method allows for the simul-
taneous assessment of ion channel inhibition activity
of e.g. up to 48 or 128 kinds of candidate drugs, in
the case of n = 8 or 3, respectively.
It is commonly thought that the usage of human cardio-
myocytes is also important in the field of pharmacological
development and drug safety testing [2, 4, 23]. Human in-
duced pluripotent stem cells (hiPSC) can efficiently differ-
entiate into cardiomyocytes in vitro [24]. We developed a
suspension culture system, which can produce large num-
bers of hiPSC-derived cardiomyocytes [25]. hiPSC-derived
cardiomyocytes have been applied for cardiac regenerative
medicine and the transplantation of an enormous number
of the cells will contribute to positive clinical therapeutic
effects [24]. At the same time those cardiomyocytes will
be also an optimal cell source for the high-throughput
investigation of ion channel inhibition and thus the detec-
tion of cardiotoxicity of drugs. Our previous report
showed that hiPSC-derived cardiomyocytes expressed
various cardiac cell-related genes, including hyperpolariza-
tion activated cyclic nucleotide-gated potassium channel 4
(HCN4), myosin light chain-2a (MLC-2a), MLC-2v, and
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Fig. 2 Inhibition of hERG currents by various hERG channel blockers. hERG currents on HEK 293 cells expressed hERG gene were detected by an
automated 384-well-patch-clamp system. hERG currents were inhibited concentration-dependently by five hERG channel blockers, astemizole (a),
cisapride (b), E-4031 (c), quinidine (d), and terfenadine (e). Left and right panels show the representative recordings of hERG current inhibition
and the inhibitory curves of hERG currents, respectively. The 50 % inhibitory concentrations (IC50) were analyzed and shown in the left upper sides
of the right panels. The n numbers were total numbers of cells at all concentrations of each drug. Three hundred eighty-four points were divided
into six, and five hERG channel blockers and no blocker were added. The error bars in the right panels show means ± SD and IC50 values
show means
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Iroquoishomeobox 4 (IRX4) [26]. HCN4 is expressed in
cardiac pacemaker cells [27]. MLC-2a is a marker of atrial
myocytes, and MLC-2v and IRX4 are those of ventricular
myocytes [28]. Thus, the data suggest that hiPSC-derived
differentiated cells contained various types of cardiomyo-
cytes including pacemaker cells, atrial and ventricular
myocytes. Currently, we are performing the patch-clamp
analysis of hiPSC-derived differentiated cardiomyocytes, the
amount of cells being expanded abundantly by the suspen-
sion culture system, using the automated 384-well-patch-
clamp system. An upgrade of the here utilized 384-well-
patch-clamp system to not only having the capability of
performing voltage-clamp, but also current-clamp record-
ings is momentarily under development. With this system
the effect of candidate drugs on the duration of the action
potentials will be investigated, which could be translated
into e.g. a prolongation of QT intervals. Additionally, the
system will allow high-throughput recordings of cardiac
subtypes including pacemaker cells, atrial myocytes, ven-
tricular myocytes, and also will allow for investigating the
maturation status of hiPSC-derived cardiomyocytes. Those
data will contribute to the field of cardiac electrophysiology
and cardiac regenerative medicine as well as pharmaceutical
development.
Conclusion
This study shows data from a hERG screening assay in an
automated high-throughput patch-clamp system. We are
confident that the method will have great impact in the field
of pharmacology, toxicology, and cardiac electrophysiology,
also in the light of the CIPA (Comprehensive In Vitro Pro-
Arrhythmia Assay) proposal that aims to define a new, inte-
grated preclinical in vitro/in silico paradigm in which the po-
tential proarrhythmic risk of a new drug would be assessed
using not only hERG patch clamp investigations, but mul-
tiple ion channel investigations (e.g. Nav1.5 and Cav1.2).
Thus, the system will contribute to the acceleration of
pharmaceutical drug-development and drug-safety testing.
Competing interests
Yuji Haraguchi and Tatsuya Shimizu have no conflicts of interest to declare.
Atsushi Ohtsuki and Takayuki Oka are employees of Nanion Technologies
GmbH. Tokyo Women’s Medical University was receiving research funds from
Nanion Technologies GmbH.
Authors’ contributions
YH, AO, and TO performed experiments and data analyses. YH and TS wrote the
manuscript. All authors have read and approved the final version of the manuscript.
Acknowledgements
We thank Merck Millipore (Billerica, MA, USA) for kindly supplying HEK 293-
hERG and CHO-hERG cells. We also thank Dr. Sonja Stölzle-Feix (Nanion
Technologies GmbH) for her useful comments and editing assistance.
This work was supported by a grant from Formation of Innovation Center
for Fusion of Advanced Technologies in the Special Coordination Funds for
Promoting Science and Technology “Cell Sheet Tissue Engineering Center
(CSTEC)” from the Ministry of Education, Culture, Sports Science, and
Technology (MEXT), Japan, and Nanion Technologies GmbH.
Author details
1Institute of Advanced Biomedical Engineering and Science, TWIns, Tokyo
Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666,
Japan. 2Nanion Technologies GmbH, Gabrielenstr.9, 80636 Munich, Germany.
Received: 22 June 2015 Accepted: 4 December 2015
References
1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates?
Nat Rev Drug Discov. 2004;3:711–5.
2. Laustriat D, Gide J, Peschanski M. Human pluripotent stem cells in drug
discovery and predictive toxicology. Biochem Soc Trans. 2010;38:1051–7.
3. Clare JJ. Targeting ion channels for drug discovery. Discov Med. 2010;9:253–60.
4. Priori SG, Napolitano C, Di Pasquale E, Condorelli G. Induced pluripotent
stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin
Invest. 2013;123:84–91.
5. Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM. Comparison of block
among cloned cardiac potassium channels by non-antiarrhythmic drugs.
Eur Heart J Supplements. 2001;3:K23–30.
6. Nakaya H. Electropharmacological assessment of the risk of drug-induced
long-QT syndrome using native cardiac cells and cultured cells expressing
HERG channels. Folia Pharmacologica Japonica. 2003;121:384–92.
7. Vonderlin N, Fischer F, Zitron E, Seyler C, Scherer D, Thomas D, et al.
Anesthetic drug midazolam inhibits cardiac human ether-à-go-go-related
gene channels: mode of action. Drug Des Devel Ther. 2015;9:867–77.
8. Neher E, Sakmann B. Single-channel currents recorded from membrane of
denervated frog muscle fibres. Nature. 1976;260:799–802.
9. Verkhratsky A, Parpura V. History of electrophysiology and the patch clamp.
Methods Mol Biol. 2014;1183:1–19.
Table 1 IC50 of hERG channel blockers
Reagents IC50
Data in this study Previous data (References)
Astemizole 6.85 nM (n = 23) 0.9 nM (2), 26 nM (4)
Cisapride 21.2 nM (n = 24) 44 nM (1), 6.9 nM (4), 23-27 nM (5)
E-4031 22.6 nM (n = 30) 18.1 nM (4), 12-17 nM (5)
Quinidine 376 nM (n = 26) 410 nM (3), 820-1,070 nM (5), 750 nM (6)
Terfenadine 41.7 nM (n = 22) 56 nM (1), 6.6-8.4 nM (5), < 52 nM (7)
References for Table 1.
1. Lacerda AE, et al.: Eur Heart J Supplements 2001, 3:K23-K30.
2. Zhou Z, et al.: J Cardiovasc Electrophysiol 1999, 10:836-843.
3. Paul AA, et al.: Br J Pharmacol 2002, 136:717-729.
4. Chiu PJ, et al.: J Pharmacol Sci 2004, 95:311-319.
5. Kirsch GE, et al.: J Pharmacol Toxicol Methods 2004, 50:93-101.
6. Wolpert C, et al.: J Cardiovasc Electrophysiol 2005, 16:54-58.
7. Katchman AN, et al.: J Pharmacol Exp Ther 2006, 316:1098-1106.
Haraguchi et al. BMC Pharmacology and Toxicology  (2015) 16:39 Page 5 of 6
10. Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, English A, et al. TRPC channel
activation by extracellular thioredoxin. Nature. 2008;451:69–72.
11. Milligan CJ, Li J, Sukumar P, Majeed Y, Dallas ML, English A, et al. Robotic
multiwell planar patch-clamp for native and primary mammalian cells.
Nat Protoc. 2009;4:244–55.
12. Stoelzle S, Obergrussberger A, Brüggemann A, Haarmann C, George M,
Kettenhofen R, et al. State-of-the-art automated patch clamp devices: heat
activation, action potentials, and high throughput in ion channel screening.
Front Pharmacol. 2011;2:76.
13. Warmke JW, Ganeztky B. A family of potassium channel genes related to
eag in Drosophila and mammals. Proc Natl Acad Sci U S A. 1994;91:3438–42.
14. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human
inward rectifier in the voltage-gated potassium channel family. Science.
1995;269:92–5.
15. Kirsch GE, Trepakova ES, Brimecombe JC, Sidach SS, Erickson HD,
Kochan MC, et al. Variability in the measurement of hERG potassium
channel inhibition: effects of temperature and stimulus pattern.
J Pharmacol Toxicol Methods. 2004;50:93–101.
16. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+)
channels: structure, function, and clinical significance. Physiol Rev.
2012;92:1393–478.
17. Jiménez-Vargas JM, Restano-Cassulini R, Possani LD. Toxin modulators and
blockers of hERG K(+) channels. Toxicon. 2012;60:492–501.
18. Weirich J, Antoni H. Rate-dependence of antiarrhythmic and proarrhythmic
properties of class I and class III antiarrhythmic drugs. Basic Res Cardiol.
1998;93 Suppl 1:125–32.
19. Yap YG, Camm AJ. Arrhythmogenic mechanisms of non-sedating
antihistamines. Clin Exp Allergy. 1999;29 Suppl 3:174–81.
20. Brown AM, Rampe D. Drug-induced long QT syndrome: Is HERG the root of
all evil? Pharmaceutical News. 2000;7:15–20.
21. Tseng GN. I(Kr): the hERG channel. J Mol Cell Cardiol. 2001;33:835–49.
22. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative
evaluation of HERG currents and QT intervals following challenge with
suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther.
2006;316:1098–106.
23. Otsuji TG, Minami I, Kurose Y, Yamauchi K, Tada M, Nakatsuji N. Progressive
maturation in contracting cardiomyocytes derived from human embryonic
stem cells: Qualitative effects on electrophysiological responses to drugs.
Stem Cell Res. 2010;4:201–13.
24. Haraguchi Y, Shimizu T, Yamato M, Okano T. Cell therapy and tissue
engineering for cardiovascular disease. Stem Cells Transl Med. 2012;1:136–41.
25. Matsuura K, Wada M, Shimizu T, Haraguchi Y, Sato F, Sugiyama K, et al.
Creation of human cardiac cell sheets using pluripotent stem cells.
Biochem Biophys Res Commun. 2012;425:321–7.
26. Haraguchi Y, Matsuura K, Shimizu T, Yamato M, Okano T. Simple suspension
culture system of human iPS cells maintaining their pluripotency for cardiac
cell sheet engineering. J Tissue Eng Regen Med. 2015;9:1363–75.
27. Ishii TM, Takano M, Xie LH, Noma A, Ohmori H. Molecular characterization
of the hyperpolarization-activated cation channel in rabbit heart sinoatrial
node. J Biol Chem. 1999;274:12835–9.
28. Lin B, Kim J, Li Y, Pan H, Carvajal-Vergara X, Salama G, et al. High-purity
enrichment of functional cardiovascular cells from human iPS cells.
Cardiovasc Res. 2012;95:327–35.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Haraguchi et al. BMC Pharmacology and Toxicology  (2015) 16:39 Page 6 of 6
